logo-loader

Insight Widest with the analysis. We look at the companies others don’t, giving access to the opportunities others won’t.

Deep dive: Health

ImmuPharma's US licensing deal provides a path to...

We take a closer look at ImmuPharma, the developer of a breakthrough drug for lupus

Giulia Bottaro

06.42 Fri 06 Dec 2019

antibody
Deep dive: Health
ImmunoPrecise Antibodies is expanding its therapeutic offerings as...
2 days, 23 hours ago
dna strand
Deep dive: Health
ReNeuron progresses as it gathers more data for developing treatments
2 days, 23 hours ago
MaxCyte Inc - MaxCyte offering exposure to 'explosive growth' in cell therapy and cellular engineering
Analyst interviews: Health
MaxCyte offering exposure to 'explosive growth' in cell therapy...
3 days, 15 hours ago
Ipsen - Open Orphan 'continuing to target rapid scale-up and profitability'
Analyst interviews: Health
Open Orphan 'continuing to target rapid scale-up and profitability'
3 days, 21 hours ago
Show all Insight news

Deep dive We explore the investor case for growth companies

pills Health

Cello Health expects "strong" full-year outcome

4 days, 23 hours ago
man with erectile dysfunction Health

Futura Medical looking ahead to completion of key phase III ED trial

6 days, 22 hours ago
lung x-ray Health

Synairgen excited for phase II trial results in 2020

1 week, 4 days ago
tablets and pills Health

AIM billionaire Clinigen is still growing at a rate of knots

1 week, 4 days ago

Watch: director interviews Hear from the directors whose companies are making the new

ImmuPharma PLC - ImmuPharma's Tim McCarthy details Lupuzor licensing deal with Avion Pharmaceuticals Health

ImmuPharma's Tim McCarthy details Lupuzor licensing deal with...

3 days, 20 hours ago
IXICO PLC - IXICO PLC reports first year of profitability 'well ahead of expectations' Health

IXICO PLC reports first year of profitability 'well ahead of...

4 days, 20 hours ago
Benchmark Holdings PLC - Benchmark Holdings moving from 'R&D investment into commercial profitability' Health

Benchmark Holdings moving from 'R&D investment into commercial...

5 days, 15 hours ago
Collagen Solutions PLC - Collagen Solutions reports particularly strong growth in its tissue business in first half Health

Collagen Solutions reports strong growth in its tissue business in...

5 days, 20 hours ago

Opinion We bridge the gap between knowledge and ignorance and give you the angle that hard facts alone won’t

Fevertree Drinks Plc - Retail & consumer

When did you get so big? Billion-pound companies that maybe you thought weren't

on 3/10/19

Feature We give you the knowledge and tools to understand and take on the market

AstraZeneca - AstraZeneca's near-£100bn valuation is a vindication for Pascal Soriot Health

AstraZeneca's near-£100bn valuation is a vindication for Pascal Soriot

1 week, 5 days ago
Robinhood Finance

Robinhood's commission-free share trading a headache for investors or rivals?

2 weeks, 5 days ago
Arecor - Health

Arecor punches above its weight with trials for fast-acting diabetes drugs

3 weeks, 4 days ago
AstraZeneca - Health

AstraZeneca and the art of resurrecting failed drug candidates

3 weeks, 6 days ago

Research Independent research from the expert Proactive analyst team

MaxCyte Inc - MaxCyte offering exposure to 'explosive growth' in cell therapy and cellular engineering

Strategic Minerals

MaxCyte offering exposure to 'explosive growth' in cell therapy and cellular engineering

Health

Open Orphan 'continuing to...

Health

MaxCyte - Pole Position in...

MaxCyte Inc (LON:MXCT) is well-positioned to leverage its proprietary flow...

Health

Open Orphan: Leveraging...

Open Orphan (ORPH) is targeting rapid scale-up and profitability in the dynamic...

Health

Shield Therapeutics:...

Meet the real story
Proactive Investors One2One Investor Forum

BeProactive

Finance

Explaining illegal market manipulation

on 12/8/19